Synthesis and characterization of novel Schiff base-silicon (IV) phthalocyanine complex for photodynamic therapy of breast cancer cell lines

Sarı, Ceren; Değirmencioğlu, İsmail; Eyüpoğlu, Figen Celep

doi:10.1016/j.pdpdt.2023.103504

Cited by 6 publications

(1 citation statement)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The calculated photodegradation quantum yields are listed in Table 1 and were 0.00021 for Si1a , 0.000192 for Q-Si1a , 0.00024 for S-Si1a , and 0.00052 for B-Si1a in DMSO. Compared to literature, the obtained results of the synthesized compounds have a high stability against light [ 38 ]. Thus, they are convenient to be used at PDT and SPDT as sensitizers, Figure S24, Table 1 .…”

Section: Resultsmentioning

confidence: 92%

Monitoring of singlet oxygen generation of a novel Schiff-base substituted silicon phthalocyanines by sono-photochemical studies and in vitro activities on prostate cancer cell

Messaoudi,

Yaşa Atmaca,

Türkkol

et al. 2024

J Biol Inorg Chem

View full text Add to dashboard Cite

This study demonstrates the potential of sono-photodynamic therapy as an effective approach for enhancing singlet oxygen generation using the synthesized Schiff-base diaxially substituted silicon phthalocyanines. In photochemical studies, the singlet oxygen quantum yields (Φ∆) were determined as 0.43 for Si1a, 0.94 for Q-Si1a, 0.58 for S-Si1a, and 0.49 for B-Sia1. In sono-photochemical studies, the Φ∆ values were reached to 0.67 for Si1a, 1.06 for Q-Si1a, 0.65 for S-Si1a, and 0.67 for B-Sia1. In addition, this study demonstrates the therapeutic efficacy of phthalocyanines synthesized as sensitizers on the PC3 prostate cancer cell line through in vitro experiments. The application of these treatment modalities exhibited notable outcomes, leading to a substantial decrease in cell viability within the PC3 prostate cancer cell line. These findings highlight the potential of utilizing these synthesized phthalocyanines as promising therapeutic agents for prostate cancer treatment. Graphical Abstract

show abstract

Section: Resultsmentioning

confidence: 92%